Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Brain Res ; 1822: 148612, 2024 01 01.
Artigo em Inglês | MEDLINE | ID: mdl-37778649

RESUMO

Alzheimer's disease (AD) is a prevalent neurodegenerative disorder characterized by neuroinflammation. Dexmedetomidine (Dex) is known for its neuroprotective properties in clinical settings. In this study, we investigated the potential of Dex in protecting against neuroinflammation in an AD mouse model induced by amyloid-beta (Aß) injection. First, in the AD mouse model, Aß injection were administered, and the model was confirmed through behavioral tests, including the Morris water maze and Y-maze. Neuroinflammatory states in Aß-injected mice were assessed using hematoxylin and eosin staining and enzyme-linked immunosorbent assay. Expression levels of microRNA (miR)-204-3p and F-box/LRR-repeat protein 7 (FBXL7) in mouse tissues were determined through real-time quantitative polymerase chain reaction and Western blot. The binding interaction between miR-204-3p and FBXL7 was elucidated using dual-luciferase analysis. Aß-injected mice exhibited cognitive impairment, neuroinflammation, and downregulated miR-204-3p. Upregulation of miR-204-3p reduced inflammatory infiltration and mitigated neuroinflammation in Aß-injected mice. Dex treatment reduced inflammation in hippocampal tissues of Aß-injected mice. Dex treatment upregulated miR-204-3p, leading to suppressed FBXL7 expression in tissues. Inhibition of miR-204-3p or overexpression of FBXL7 reversed the alleviating effect of Dex on neuroinflammation in Aß-injected mice. Overall, Dex increased miR-204-3p expression, resulting in the inhibition of FBXL7, and subsequently alleviated neuroinflammation in Aß-injected mice.


Assuntos
Doença de Alzheimer , Dexmedetomidina , MicroRNAs , Animais , Camundongos , Doença de Alzheimer/tratamento farmacológico , Doença de Alzheimer/metabolismo , Peptídeos beta-Amiloides/metabolismo , Dexmedetomidina/farmacologia , MicroRNAs/metabolismo , Doenças Neuroinflamatórias/tratamento farmacológico , Doenças Neuroinflamatórias/metabolismo , Proteínas F-Box/efeitos dos fármacos , Proteínas F-Box/metabolismo
2.
Sci Rep ; 9(1): 18694, 2019 12 10.
Artigo em Inglês | MEDLINE | ID: mdl-31822720

RESUMO

Metformin is used to treat type 2 diabetes. Metformin activates AMP-activated kinase (AMPK), which may contribute to the action of metformin. Metformin also shows anti-proliferation activity. However, the mechanism is remained unknown. We found that treatment of MCF-7 cells with metformin induced the demethylase activity of KDM2A in the rDNA promoter, which resulted in reductions of rRNA transcription and cell proliferation. AMPK activity was required for activation of KDM2A by metformin. Because demethylase activities of JmjC-type enzymes require a side reaction converting α-ketoglutarate to succinate, these organic acids may affect their demethylase activities. We found that metformin did not induce KDM2A demethylase activity in conditions of a reduced level of α-ketoglutarate. A four-hour treatment of metformin specifically reduced succinate, and the replenishment of succinate inhibited the activation of KDM2A by metformin, but did not inhibit the activation of AMPK. Metformin reduced succinate even in the conditions suppressing AMPK activity. These results indicate that metformin activates AMPK and reduces the intracellular succinate level, both of which are required for the activation of KDM2A to reduce rRNA transcription. The results presented here uncover a novel factor of metformin actions, reduction of the intracellular succinate, which contributes to the anti-proliferation activity of metformin.


Assuntos
Proteínas F-Box/metabolismo , Histona Desmetilases com o Domínio Jumonji/metabolismo , Metformina/metabolismo , Proteínas Quinases Ativadas por AMP/metabolismo , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , DNA Ribossômico/genética , Diabetes Mellitus Tipo 2/genética , Proteínas F-Box/efeitos dos fármacos , Proteínas F-Box/genética , Glucose/metabolismo , Histonas/metabolismo , Humanos , Hipoglicemiantes/farmacologia , Histona Desmetilases com o Domínio Jumonji/efeitos dos fármacos , Células MCF-7 , Metformina/farmacologia , Regiões Promotoras Genéticas/efeitos dos fármacos , RNA Ribossômico/metabolismo , Ácido Succínico/metabolismo , Transcrição Gênica/efeitos dos fármacos
3.
Toxicol Appl Pharmacol ; 355: 247-256, 2018 09 15.
Artigo em Inglês | MEDLINE | ID: mdl-30017639

RESUMO

Bisphenol A (BPA) impairs male fertility by acting as an endocrine disruptor. However, the mechanisms by which BPA cause reproductive toxicity are not fully elucidated. Here, we explored the role of XAF1, a novel pro-apoptosis molecule, in BPA-induced abnormal spermatogenesis and the transcriptional regulation mechanism of BPA-induced XAF1. BPA exposure detrimentally impacted spermatogenesis by inducing excessive germ cell apoptosis. XAF1 was upregulated in germ cells after BPA exposure, which was involved in the apoptosis pathway. In addition, the expression levels of XIAP and XAF1 were inversely correlated after BPA exposure. Knockdown of XAF1 expression partially inhibited the apoptosis of GC-2 cells, suppressed the activation of caspase 3 and improved the BPA-induced XIAP expression. Moreover, IFNß expression levels were significantly upregulated after BPA exposure both in vitro and in vivo, and these levels were positively related to the expression of XAF1. Furthermore, IFNß knockdown reduced the expression of XAF1 and increased the expression of XIAP in BPA-treated GC-2 cells. Together, these data indicated that BPA triggers male germ cell apoptosis in mice via the IFNß-XAF1-XIAP pathway, which may contribute to BPA-induced testis toxicity.


Assuntos
Apoptose/efeitos dos fármacos , Compostos Benzidrílicos/toxicidade , Proteínas F-Box/efeitos dos fármacos , Células Germinativas/efeitos dos fármacos , Proteínas Inibidoras de Apoptose/efeitos dos fármacos , Interferon beta/efeitos dos fármacos , Fenóis/toxicidade , Transdução de Sinais/efeitos dos fármacos , Proteínas Adaptadoras de Transdução de Sinal , Animais , Proteínas Reguladoras de Apoptose , Linhagem Celular , Proteínas F-Box/genética , Expressão Gênica/efeitos dos fármacos , Técnicas de Silenciamento de Genes , Proteínas Inibidoras de Apoptose/genética , Interferon beta/genética , Masculino , Camundongos , Espermatogênese/efeitos dos fármacos , Testículo/patologia , Regulação para Cima/efeitos dos fármacos
4.
J Neurosci ; 36(41): 10560-10573, 2016 10 12.
Artigo em Inglês | MEDLINE | ID: mdl-27733608

RESUMO

Demyelinating diseases, such as multiple sclerosis, are known to result from acute or chronic injury to the myelin sheath and inadequate remyelination; however, the underlying molecular mechanisms remain unclear. Here, we performed genome occupancy analysis by chromatin immunoprecipitation sequencing in oligodendrocytes in response to lysolecithin-induced injury and found that Olig2 and its downstream target Gpr17 are critical factors in regulating oligodendrocyte survival. After injury to oligodendrocytes, Olig2 was significantly upregulated and transcriptionally targeted the Gpr17 locus. Gpr17 activation inhibited oligodendrocyte survival by reducing the intracellular cAMP level and inducing expression of the pro-apoptotic gene Xaf1 The protein kinase A signaling pathway and the transcription factor c-Fos mediated the regulatory effects of Gpr17 in oligodendrocytes. We showed that Gpr17 inhibition elevated Epac1 expression and promoted oligodendrocyte differentiation. The loss of Gpr17, either globally or specifically in oligodendrocytes, led to an earlier onset of remyelination after myelin injury in mice. Similarly, pharmacological inhibition of Gpr17 with pranlukast promoted remyelination. Our findings indicate that Gpr17, an Olig2 transcriptional target, is activated after injury to oligodendrocytes and that targeted inhibition of Gpr17 promotes oligodendrocyte remyelination. SIGNIFICANCE STATEMENT: Genome occupancy analysis of oligodendrocytes in response to lysolecithin-mediated demyelination injury revealed that Olig2 and its downstream target Gpr17 are part of regulatory circuitry critical for oligodendrocyte survival. Gpr17 inhibits oligodendrocyte survival through activation of Xaf1 and cell differentiation by reducing Epac1 expression. The loss of Gpr17 in mice led to precocious myelination and an earlier onset of remyelination after demyelination. Pharmacological inhibition of Gpr17 promoted remyelination, highlighting the potential for Gpr17-targeted therapeutic approaches in demyelination diseases.


Assuntos
Fatores de Transcrição Hélice-Alça-Hélice Básicos/genética , Fatores de Transcrição Hélice-Alça-Hélice Básicos/metabolismo , Sobrevivência Celular/efeitos dos fármacos , Doenças Desmielinizantes/induzido quimicamente , Doenças Desmielinizantes/patologia , Lisofosfatidilcolinas/toxicidade , Proteínas do Tecido Nervoso/genética , Proteínas do Tecido Nervoso/metabolismo , Oligodendroglia/efeitos dos fármacos , Receptores Acoplados a Proteínas G/metabolismo , Proteínas Adaptadoras de Transdução de Sinal , Animais , Proteínas Reguladoras de Apoptose , Diferenciação Celular/efeitos dos fármacos , Cromonas/farmacologia , Mapeamento Cromossômico , AMP Cíclico/metabolismo , Proteínas Quinases Dependentes de AMP Cíclico/efeitos dos fármacos , Proteínas F-Box/efeitos dos fármacos , Fatores de Troca do Nucleotídeo Guanina/biossíntese , Fatores de Troca do Nucleotídeo Guanina/genética , Antagonistas de Leucotrienos/farmacologia , Camundongos , Camundongos Endogâmicos C57BL , Fator de Transcrição 2 de Oligodendrócitos , Proteínas Proto-Oncogênicas c-fos/efeitos dos fármacos , Receptores Acoplados a Proteínas G/genética , Transdução de Sinais/efeitos dos fármacos
5.
Cell Rep ; 15(1): 210-218, 2016 Apr 05.
Artigo em Inglês | MEDLINE | ID: mdl-27052166

RESUMO

Studying the role of essential proteins is dependent upon a method for rapid inactivation, in order to study the immediate phenotypic consequences. Auxin-inducible degron (AID) technology allows rapid depletion of proteins in animal cells and fungi, but its application to human cells has been limited by the difficulties of tagging endogenous proteins. We have developed a simple and scalable CRISPR/Cas-based method to tag endogenous proteins in human HCT116 and mouse embryonic stem (ES) cells by using donor constructs that harbor synthetic short homology arms. Using a combination of AID tagging with CRISPR/Cas, we have generated conditional alleles of essential nuclear and cytoplasmic proteins in HCT116 cells, which can then be depleted very rapidly after the addition of auxin to the culture medium. This approach should greatly facilitate the functional analysis of essential proteins, particularly those of previously unknown function.


Assuntos
Proteínas de Arabidopsis/genética , Proteínas F-Box/genética , Marcação de Genes/métodos , Genes Essenciais , Ácidos Indolacéticos/farmacologia , Proteólise , Receptores de Superfície Celular/genética , Animais , Proteínas de Arabidopsis/efeitos dos fármacos , Sistemas CRISPR-Cas , Células-Tronco Embrionárias/metabolismo , Proteínas F-Box/efeitos dos fármacos , Células HCT116 , Humanos , Camundongos , Receptores de Superfície Celular/efeitos dos fármacos , Homologia de Sequência
6.
Aging (Albany NY) ; 5(2): 111-9, 2013 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-23454868

RESUMO

FBXW7 acts as a tumor suppressor in numerous types of human cancers through ubiquitination of different oncoproteins including mTOR. However, how the mutation/loss of Fbxw7 results in tumor development remains largely unknown. Here we report that downregulation of mTOR by radiation is Fbxw7-dependent, and short-term mTOR inhibition by rapamycin after exposure to radiation significantly postpones tumor development in Fbxw7/p53 double heterozygous (Fbxw7+/-p53+/-) mice but not in p53 single heterozygous (p53+/-) mice. Tumor latency of rapamycin treated Fbxw7+/-p53+/- mice is remarkably similar to those of p53+/- mice while placebo treatedFbxw7+/-p53+/- mice develop tumor significantly earlier than placebo treated p53+/- mice. Furthermore, we surprisingly find that, although temporal treatment of rapamycin is given at a young age, the inhibition of mTOR activity sustainably remains in tumors. These results indicate that inhibition of mTOR signaling pathway suppresses the contribution of Fbxw7 loss toward tumor development.


Assuntos
Transformação Celular Neoplásica/genética , Proteínas F-Box/genética , Neoplasias Induzidas por Radiação/tratamento farmacológico , Sirolimo/farmacologia , Serina-Treonina Quinases TOR/genética , Ubiquitina-Proteína Ligases/genética , Animais , Transformação Celular Neoplásica/efeitos dos fármacos , Proteínas F-Box/efeitos dos fármacos , Proteína 7 com Repetições F-Box-WD , Genes Supressores de Tumor , Camundongos , Mutação , Transdução de Sinais , Serina-Treonina Quinases TOR/efeitos dos fármacos , Ubiquitina-Proteína Ligases/efeitos dos fármacos
7.
Biol Reprod ; 86(4): 114, 2012 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-22302686

RESUMO

Precise coordination of meiotic progression is a critical determinant of an egg's capacity to be fertilized successfully, and zinc has emerged as a key regulatory element in this process. An early manifestation of a regulatory role for this transition metal is the significant increase in total intracellular zinc. This accumulation is essential for meiotic progression beyond telophase I and the establishment of meiotic arrest at metaphase II. The subsequent developmental event, fertilization, induces a rapid expulsion of labile zinc that is a hallmark event in meiotic resumption. In the present study, we show that the zinc fluxes work, in part, by altering the activity of the cytostatic factor (CSF), the cellular activity required for the establishment and maintenance of metaphase II arrest in the mature, unfertilized egg. We propose a model in which zinc exerts concentration-dependent regulation of meiosis through the CSF component EMI2, a zinc-binding protein. Together, the data support the conclusion that zinc itself, through its interaction with EMI2, is a central component of the CSF.


Assuntos
Pontos de Checagem do Ciclo Celular/fisiologia , Proteínas F-Box/fisiologia , Meiose/fisiologia , Oócitos/citologia , Proteínas Proto-Oncogênicas c-mos/fisiologia , Zinco/fisiologia , Animais , Pontos de Checagem do Ciclo Celular/efeitos dos fármacos , Quelantes/farmacologia , Etilenodiaminas/farmacologia , Proteínas F-Box/efeitos dos fármacos , Feminino , Meiose/efeitos dos fármacos , Camundongos , Oócitos/química , Oócitos/efeitos dos fármacos , Proteínas Proto-Oncogênicas c-mos/efeitos dos fármacos , Zinco/deficiência
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA